BHCM
EBS icon

Boulder Hill Capital Management’s Emergent Biosolutions EBS Stock Holding History

Boulder Hill Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,000
Closed -$169K – 111
2023
Q2 		$169K Sell
23,000
-17,600
-43% -$163K 0.33% 74
2023
Q1 		$421K Buy
+40,600
New +$491K 0.34% 59

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Boulder Hill Capital Management's EBS Position: Q3 2023 in Review

Boulder Hill Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 23,000 shares — an estimated $169K sold.

Boulder Hill Capital Management first reported a position in EBS in Q1 2023 and held it in 2 quarters. The position peaked at $421K in Q1 2023. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

  • Boulder Hill Capital Management reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 23,000 Emergent Biosolutions shares in Q3 2023, an estimated $169K.
  • Boulder Hill Capital Management first reported a position in Emergent Biosolutions in Q1 2023 and held it in 2 quarters.
  • Boulder Hill Capital Management's Emergent Biosolutions position peaked at $421K in Q1 2023.
  • 162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Boulder Hill Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.